Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
489 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07176052 | Expectation, Pain Outcomes, and Pain Medication Following Oncology Abdominal Surgery: A Cohort Study | not yet recruiting | — | 200 | Rigshospitalet, DenmarkOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT06831136 | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma(PANCARDINAL-2) | recruiting | Phase 2 | 24 | The University of Texas Health Science Center, HoustonOTHER |
| 1 |
| Sep 10, 2025 |
| clinicaltrials |
| NCT05209074 | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 16 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer(RAMP205) | active not recruiting | Phase 1 / Phase 2 | 40 | Verastem, Inc.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06202131 | Use of Ctdna in Patients With Gastrointestinal Tract Tumors(ctdna-GI) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06728358 | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract(SOCRATE) | active not recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT05470920 | Genetic Testing Decision Aid | recruiting | N/A | 350 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06149689 | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer(PTCA199-7) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06250972 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer(PTCA199-11) | recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07101679 | A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer | recruiting | Phase 2 | 23 | West China HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07034339 | Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution | recruiting | — | 1,500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06595160 | Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy | recruiting | — | 87 | Emory UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097064 | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers(RAIPANC) | not yet recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07093593 | Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs(RAMA) | not yet recruiting | N/A | 260 | Centre Georges Francois LeclercOTHER | 0 | Jul 30, 2025 | clinicaltrials |
| NCT07080021 | A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer(MRD) | recruiting | — | 119 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05625529 | ExoLuminate Study for Early Detection of Pancreatic Cancer | recruiting | — | 1,000 | Biological DynamicsINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT03806309 | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC(TEDOPAM) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07066995 | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer(BAH2573-102) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06287749 | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) | recruiting | — | 37 | University Hospital, MontpellierOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 60 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07045571 | MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer | recruiting | — | 1,000 | Yingbin Liu, MD, PhD, FACSOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05241249 | Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | recruiting | Phase 2 | 37 | Susan E. BatesOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06277531 | Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)(ECCBILE) | recruiting | — | 99 | Peking University Third HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT03073785 | Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 46 | University of NebraskaOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06538857 | CEB-01 in Locally Resectable Pancreatic Cancer | recruiting | Phase 2 | 39 | CEBIOTEXINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT06967662 | Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)(INTRACOR_pilot) | enrolling by invitation | N/A | 28 | Ilyinskaya Hospital, JSCOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06515587 | Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer | recruiting | N/A | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05518643 | Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes | recruiting | — | 120 | University of ThessalyOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | active not recruiting | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06913218 | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | not yet recruiting | Phase 1 | 60 | AkesoINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911021 | 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT02818829 | Biological and Clinical Database for Pancreatic Adenocarcinoma(BACAP) | active not recruiting | — | 1,700 | University Hospital, ToulouseOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06638866 | AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort(AI-PANC) | recruiting | — | 5,000 | Changhai HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04246203 | Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer(PROJECTION) | active not recruiting | — | 200 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06743386 | Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )(RadioFAP) | not yet recruiting | N/A | 30 | French Society of Digestive EndoscopyOTHER | 0 | Mar 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2025source: clinicaltrials